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clinical outcomes in patients with ST-
elevation myocardial infarction
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Abstract
Background: It remained unclear whether the combination of the Canada Acute Coronary Syndrome Risk
Score (CACS-RS) and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) could have a better performance
in predicting clinical outcomes in acute ST-elevation myocardial infarction (STEMI) patients with primary percutaneous
coronary intervention.
Methods: A total of 589 consecutive STEMI patients were enrolled. The potential additional predictive value
of NT-pro-BNP with the CACS-RS was estimated. Primary endpoint was in-hospital mortality and long-term
poor outcomes.
Results: The incidence of in-hospital death was 3.1%. Patients with higher NT-pro-BNP and CACS-RS had a
greater incidence of in hospital death. After adjustment for the CACS-RS, elevated NT-pro-BNP (defined as the
best cutoff point based on the Youden’s index) was significantly associated with in hospital death (odd ratio
= 4.55, 95%CI = 1.52–13.65, p = 0.007). Elevated NT-pro-BNP added to CACS-RS significantly improved the C-
statistics for in-hospital death, as compared with the original score (0.762 vs. 0.683, p = 0.032). Furthermore,
the addition of NT-pro-BNP to CACS-RS enhanced net reclassification improvement (0.901, p < 0.001) and
integrated discrimination improvement (0.021, p = 0.033), suggesting effective discrimination and reclassification. In
addition, the similar result was also demonstrated for in-hospital major adverse clinical events (C-statistics: 0.736 vs. 0.695,
p = 0.017) or 3-year mortality (0.699 vs. 0.604, p = 0.004).
Conclusions: Both NT-pro-BNP and CACS-RS are risk predictors for in hospital poor outcomes in patients with STEMI. A
combination of them could derive a more accurate prediction for clinical outcome s in these patients.
Keywords: N-terminal pro-brain natriuretic peptide, Canada Acute Coronary Syndrome Risk Score, Acute ST-elevation
myocardial infarction
Background
Despite significant advances in treatment and preven-
tion, patients with ST-elevation myocardial infarction
(STEMI) still remained important population with high
risk of adverse clinical outcomes [1], especially in
developed countries [2]. Accurate and comprehensive
simple risk evaluation plays an important role for these
patients in appropriate therapeutic decision making.
Therefore, several prognostic risk scores have been
established to identify high-risk patients and provide
important prognostic information, such as the Global
Registry of Acute Coronary Events (GRACE) risk score
[3, 4]. Recently, Fabrizio D'Ascenzo et al demonstrated
that Thrombolysis in Myocardial Infarction (TIMI) and
GRACE are the risk scores that up until now have been
most extensively investigated, and GRACE was better
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than others [5]. However, these risk scores are not
widely used in clinical practice because they contain
many variables that may not be easily applicable before
hospital admission or in the emergency department,
and they require computerized calculation methods. Re-
cently, the Canada Acute Coronary Syndrome Risk Score
(CACS-RS), has been shown to permit rapid stratification
of patients with acute coronary syndrome (ACS) [6]. Be-
cause this risk score is simple and easy to memorize and
calculate, it can be comfortably used by health care pro-
fessionals without advanced medical training. However,
the predictive value of CACS-RS in selected STEMI
patients remains unknown.
N-terminal-pro-brain natriuretic peptide (NT-pro-BNP)
is secreted in response to cardiac hemodynamic stress me-
diated by volume and pressure overload [7]; NT-pro-BNP
is very stable at room temperature and is often measured in
clinical practices, especially in the emergency department.
NT-pro-BNP has been proposed to provide prognostic in-
formation in patients with acute coronary syndrome (ACS)
[8]. The current clinical cardiology guidelines also recom-
mended the use of selected newer biomarkers, including
NT-pro-BNP, to provide additional prognostic information
in patients with non-ST-elevation ACS [9, 10]. However,
there has been no simple and effective risk model in-
corporating NT-pro-BNP for predicting the prognosis
of STEMI patients.
Therefore, the present study was conducted to validate
the predictive value of CACS-RS for STEMI patients,
and to develop a Bio-Clinical CACS-RS (Bio-C-CACS)
incorporating NT-pro-BNP to evaluate whether Bio-C-
CACS would improve the ability to predict clinical poor
outcomes compared with CACS-RS in those patients




According to our institute’s protocol, we enrolled all
consecutive patients who were admitted to Guangdong
Cardiovascular Institute of Guangdong General Hospital,
Guangdong Academy of Medical Sciences, between
March 2008 and October 2012. These patients presented
within 12 h of onset of cardiac symptoms with ST-
segment elevation undergoing PPCI and admitted to the
coronary care unit within at least 48 h of admission. Pa-
tients with cardiac shock on admission, patients with
chronic peritoneal or hemodialysis treatment were ex-
cluded. Patients without pre-procedural NT-pro-BNP
levels, or with severe liver or kidney dysfunction, or
malignancy were also excluded.
The local ethics committee of our institute ap-
proved the study protocol. Written informed consent
was obtained from the patients before the procedure,
or from next of kin for patients who could not sign
the informed consent themselves.
Study protocol and Risk calculation
The baseline patient demographic data, cardiovascular
risk factors, cardiac history, clinical data, and in-hospital
medications of all the patients were recorded. NT-pro-
BNP was measured using an electro-chemiluminescence
immunoassay (Roche Diagnostics, Germany) at hospital
admission before the procedure. Other clinical parame-
ters, such as serum creatinine, cardiac troponin I, creatine
kinase MB, and levels of electrolytes were measured as a
part of standard clinical care. The estimated glomerular
filtration rate (eGFR) was calculated using the four-
variables of the Modification of Diet in Renal Disease
equation for Chinese patients [11].
For each patient, we used the CACS-RS model at
admission to estimate the risks for in-hospital and
follow-up patient outcomes. The CACS-RS ranged from
0 to 4, with 1 point assigned for the presence of each of
these variables: age ≥75 years, Killip > 1, systolic blood
pressure <100 mmHg, and heart rate >100 beats/min
(Table 1).
PCI procedure and medications
Primary PCI was performed with standard technique
according to our institute’s protocol and AHA/ACC
guidelines for the management of patients with STEMI.
The use of anti-platelet agents (aspirin/clopidogrel), β-
adrenergic blocking agents, angiotensin-converting
enzyme inhibitors, statins, or inotropic drug support
was left at the clinician’s discretion according to clinical
protocols.
Follow-up and Clinical endpoints
All patients were followed up at least 3 years after the
PCI procedure. The follow up data were obtained by
reviewing medical records or through a telephone inter-
view with patients.
The primary end point was in-hospital mortality. The
secondary end point was the incidence of in hospital
major adverse clinical events (MACEs: including all
causes mortality, nonfatal myocardial infarction, target-
vessel revascularization, and cerebrovascular events) and
3-year all cause mortality [12].
Table 1 The variables in the CACS risk score
Variables Scores
Age ≥75 years 1
Killip > 1 1
Systolic blood pressure < 100 mmHg 1
Heart rate > 100 beats/min 1
Abbreviation: CACS Canada Acute Coronary Syndrome
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Statistical analysis
Continuous variables were expressed as mean ± standard
deviation or median values with interquartile ranges
(IQR), where appropriate. Categorical variables were
expressed as absolute number (percentage). The Stu-
dent’s t-test and Mann-Whitney U test were applied to
compare normally and non-normally distributed con-
tinuous variables, respectively. The best cut-off value of
NT-pro-BNP for predicting in hospital mortality was de-
termined by the receiver-operating characteristic (ROC)
curves analysis. The differences in clinical characteristics
between patients with higher or lower than this cut-off
value were compared. Multivariable logistic regression
was performed by forward stepwise selection to evaluate
the independent value of NT-pro-BNP as a categorical
variable (based on the cut-off value) for in -hospital
mortality, after adjusting the CACS-RS or variables, with
p values <0.15 in the univariate analysis. Then, a new
score, the Bio-C-CACS was obtained by adding the
points based on the association between the CACS-RS
regression coefficient and the NT-pro-BNP coefficient, if
NT-pro-BNP was higher than its cut-off. The discrimin-
ation between NT-pro-BNP, CACS-RS and Bio-C-CACS
risk score for in-hospital mortality or MACEs were eval-
uated with ROC area under the curve (AUC), sensitivity,
and specificity.
The AUC was compared using the nonparametric ap-
proach of DeLong et al. [13]. Calibration was evaluated
using the Hosmere-Lemeshow goodness-of-fit. We also
performed net reclassification improvement (NRI) and
integrated discrimination improvement (IDI) to analyze
the degree to which the addition of NT-pro-BNP to the
CACS-RS improved predictive ability [14]. All data ana-
lysis was performed using SAS version 9.4 (SAS Insti-
tute, Cary, NC). All statistical tests were two-tailed and
statistical significance was accepted at p < 0.05.
Results
Baseline clinical characteristics and clinical outcomes
A total of 589 patients were included in the study. 16.3%
were female. The percentages of patients complicated
with diabetes, hypertension, and who were smokers were
21.6%, 54.3% and 48.9%, respectively. The mean age was
63.0 ± 11.9 years, mean eGFR was 77.70 ± 26.5 mL/min/
1.73m2. NT-pro-BNP showed a median of 1244 pg/mL
(IQR = 515-2704). The CACS-RS showed a median of 1
(IQR = 0-1), with 45.84% being low risk (0-1), 51.61%
medium risk (1-3) and 2.55% high risk (≥3).
From the CACS-RS low risk to high risk, there was a
positive trend with older age, NT-pro-BNP levels, and
the pre-procedural SCr level. There was a negative trend
with the pre-procedural renal function and left ventricu-
lar ejection fraction (LVEF). However, there were no
significant differences in the incidence of hypertension,
diabetes, or previous myocardial infarction among the
different risk groups of CACS- RS (Table 2).
Overall, the incidence of in-hospital mortality was
3.1%, and the MACEs were 23.8%. The median follow-
up period was 3.54 ± 1.40 years (inter quartile range,
2.61–4.28 years). During patient follow up, 3-year all
cause mortality developed in 26 patients (5.9%).
Predictive value of CACS-RS
Patients who developed in-hospital mortality pre-
sented with a higher CACS-RS than those without
(1.50 vs. 0.71, p = 0.008). The similar results were also
demonstrated in patients developed in hospital
MACEs or 3-year mortality (1.21 vs. 0.59, p < 0.001;
1.16 vs. 0.67, p < 0.001). The predictive value of
CACS-RS for in hospital mortality was 0.683 (95% CI
= 0.551-0.816) (Fig. 1). CACS-RS also showed predictive
accuracy for in hospital MACEs (Fig. 1) or 3-year all cause
mortality, with C-statistics of 0.695 (95% CI = 0.650-
0.741), 0.604(95% CI = 0.515- 0.694).
Independent Predictive value of NT-pro-BNP
In addition, the best cut-off value of NT-pro-BNP for
predicting in-hospital mortality was 2300 pg/mL with
72.2% sensitivity and 73.0% specificity, based on the
Youden index. Furthermore, comparing to patients with
low NT-pro-BNP (<2300 pg/mL), patients with NT-pro-
BNP ≥2300 pg/mL presented with a significantly higher
in-hospital mortality (7.74% vs. 1.19%, p < 0.001) or in
hospital MACEs (42.86% vs. 16.15%, p < 0.001). The
Kaplan-Meier curve showed that the incidence of MACEs
was higher in those patients with higher NT-pro-BNP
levels. Log-rank test on the curves demonstrated signifi-
cant difference between two groups (Chi square = 15.56,
P < 0.001).
Univariate logistic regression analysis showed that NT-
pro-BNP ≥2300 pg/mL was significantly associated with
in-hospital mortality (OR = 6.98, 95% CI = 2.45–19.90,
p < 0.001). Additional significant variables included
CACS-RS (OR = 2.76, 95% CI, 1.64–4.66, p < 0.001).
The multivariate analysis, together with CACS-RS and
NT-pro-BNP (as a categorical variable) demonstrated that
CACS-RS and NT-pro- BNP ≥2300 pg/mL remained the
significant independent predictor of in hospital mortality
(OR = 2.15, 95%CI, 1.24–3.75, p = 0.007; OR = 4.55, 95%
CI, 1.52–13.65, p = 0.007).
Combination of NT-pro-BNP with the CACS-RS
In order to evaluate the additional predictive value of
NT-pro-BNP to CACS-RS, the NT-pro-BNP (as a
categorical variable, according to the cut-off value)
was incorporated into the new score (Bio-C-CACS-
RS). Combinations of NT-pro-BNP with CACS-RS
might more accurately identify patients at high risk of
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in hospital mortality or MACEs than using CACS-RS
only. (Fig. 2)
In addition, ROC analysis demonstrated that the AUC for
in hospital mortality increased significantly after the
addition of NT-pro-BNP to the CACS-RS (AUC: 0.762 vs.
0.683; p = 0.032), as did the Hosmer-Lemeshow goodness
of fit (X2 = 7.44, p = 0.489). (Fig. 1) More importantly, the
inclusion of NT-pro-BNP into the CACS-RS was associated
with a NRI of 90.1%, suggesting effective reclassification.
The IDI showed that the model diagnostic performance
was significantly improved by adding NT-pro-BNP to the
CACS-RS (IDI = 0.021, p = 0.033).
Meanwhile, applying the same statistic metrics to other
clinical endpoints, we found that NT-pro-BNP increased
the AUC, and improved the reclassification and discrimin-
ation ability when added to the CACS-RS, with in-hospital
MACEs: (AUC: 0.736 vs. 0.695, IDI: 0.032, NRI: 0.601); 3-
year all cause mortality: (AUC: 0.699 vs. 0.604, IDI: 0.032,
NRI: 0.762).
Discussions
This study demonstrated that CACS-RS is an inde-
pendent predictor of outcomes in STEMI patients
undergoing PPCI, and with good predictive value of
poor outcomes. Furthermore, this might be the first
study to demonstrate that the measurement of NT-
pro-BNP concentrations on patient hospital admission
add prognostic information about short- and long-
Table 2 Baseline characteristics of patients according to C-ACS-RS group
Variables 0 (n = 266) 1 (n = 217) 2 (n = 95) ≥3 (n = 11) P value
Demographics
Age, years 58.32 ± 9.84 64.41 ± 11.93 71.08 ± 11.22 77.55 ± 6.31 <0.001
Age≥ 75 years, n (%) 0 (0.0%) 46 (21.2%) 45 (47.4%) 8 (72.7%) <0.001
Female, n (%) 34 (12.8%) 41 (18.9%) 20 (21.1%) 1 (9.1%) 0.140
Systolic BP (mmHg) 125.36 ± 16.16 117.79 ± 21.45 113.28 ± 29.40 98.30 ± 27.75 <0.001
Diastolic BP (mmHg) 76.22 ± 40.09 71.02 ± 14.00 67.00 ± 16.34 59.70 ± 14.49 0.028
Heart rate (beat/min) 76.88 ± 11.23 79.77 ± 16.92 85.70 ± 24.54 86.70 ± 18.56 <0.001
Medical history, n (%)
Diabetes 56 (21.1%) 48 (22.1%) 19 (20.0%) 4 (36.4%) 0.760
Previous myocardial infarction 12 (4.5%) 14 (6.5%) 5 (5.3%) 2 (18.2%) 0.240
Coronary artery bypass graft 11 (4.1%) 6 (2.8%) 10(10.5%) 2(18.2%) 0.005
Hypertension 135 (50.8%) 121 (55.8%) 56 (58.9%) 8 (72.7%) 0.276
Smoking 138 (51.9%) 102 (47.0%) 43 (45.3%) 5 (45.5%) 0.612
Anemia 78 (29.3%) 45 (20.7%) 16 (16.8%) 2 (18.2%) 0.040
Laboratory findings
NT-pro-BNP, pg/mL(Median) 851.15 1506.00 2414.00 2330.00 <0.001
Lg NT-pro-BNP, pg/mL 6.61 ± 1.27 7.28 ± 1.23 7.81 ± 1.26 7.85 ± 1.46 <0.001
Pre-procedural SCr (μmol/L) 91.24 ± 44.05 101.04 ± 39.58 111.49 ± 52.16 171.92 ± 147.90 <0.001
eGFR, mL/min/1.73 m2 90.59 ± 94.56 78.16 ± 38.82 66.34 ± 21.50 50.97 ± 26.01 0.008
LVEF, % 55.54 ± 10.42 53.54 ± 10.31 49.04 ± 10.85 51.67 ± 14.62 <0.001
Hemoglobin (g/L) 135.33 ± 16.32 131.13 ± 17.97 127.39 ± 17.10 132.52 ± 18.79 <0.001
Hemoglobin A1c (%) 6.47 ± 1.36 6.62 ± 1.74 6.30 ± 1.39 6.44 ± 0.64 0.554
Serum albumin (g/L) 34.47 ± 5.24 32.71 ± 4.30 31.58 ± 4.47 31.27 ± 4.85 <0.001
Uric acid (μmol/L) 358.13 ± 93.3 377.69 ± 124.2 380.06 ± 117.7 393.11 ± 79.9 0.265
Procedural characteristic
Contrast volume (mL) 132.80 ± 53.81 132.92 ± 53.00 144.29 ± 43.39 187.50 ± 81.32 0.291
Contrast exposure time (min) 78.89 ± 42.27 82.52 ± 37.72 92.02 ± 42.80 80.00 ± 49.50 0.347
Number of diseased vessels (n) 1.99 ± 1.17 2.08 ± 0.90 2.26 ± 0.94 2.00 ± 0.77 0.197
Number of stents (n) 1.36 ± 0.82 1.40 ± 0.77 1.49 ± 0.84 1.36 ± 0.50 0.587
Total length of stent (mm) 37.04 ± 26.47 35.61 ± 23.55 37.05 ± 24.60 24.00 ± 8.49 0.871
Abbreviation: C-ACS-RS Canada Acute Coronary Syndrome risk score, NT-pro-BNP N-terminal-pro-brain natriuretic peptide, SCr serum creatinine, eGFR estimated
glomerular filtration rate, LVEF left ventricular ejected function
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term outcomes to the CACS-RS. This study has de-
scribed the use of the new Bio-C-CACS.
STEMI patients remain an important clinical population
with a risk of adverse clinical outcomes [2]. In the present
study, the in hospital mortality of STEMI patients was
shown to be 3.1% and the 3-year mortality was 5.9%,
which was lower than the incidence of mortality in the
study by Campo G et al [15–17]. It might be related to the
different percentage of hypertension, previous myocardial
infraction and the type of stent. The findings in present
and previous studies support the aim of this study, to
develop improved clinical tools to identify STEMI patients
at high risk of poor clinical outcome. Accurate and com-
prehensive simple risk evaluation plays an important role
for these patients in appropriate therapeutic decision
making. Higher risk scores usually imply that higher-
intensity treatments may be appropriate within the
context of the patient’s health status. However, inappro-
priate use of aggressive medical management in pa-
tients at low-risks may only expose them to experience
adverse effects.
Several risk-scoring systems have been proven to evalu-
ate the risk of poor clinical outcomes in STEMI patients.
The GRACE risk score is one of the most frequently used
models, incorporating clinical investigation (such as an
ECG) and cardiac and renal biomarker (such as creatinine
kinase MB and serum creatinine levels). However, the
GRACE risk score requires computerized calculation
methods, and not all clinical information for this assess-
ment may be available at first clinical contact. In
addition, the TIMI score for STEMI is an another popu-
lar risk-assessment tool, which is simpler to use than
the GRACE score, but may also require the availability
of an ECG and patient weight on admission [18]. Fur-
thermore, previous research has shown that the Mehran
risk score (MRS) for contrast-induced nephropathy can
be applied to stratify STEMI patients for poor clinical
outcomes both in the short- and long-term follow-up.
However, the MRS incorporates eight variables, which
include not only the history of previous diseases, but
also the procedure-related variables (such as contrast
volume), and cannot be used before the procedure [19].
The clinical SYNTAX risk score is used for identifying
STEMI patients for poor clinical outcomes, and was
based on the anatomy of the coronary diseases following
Fig. 2 Incidence of in-hospital mortality (a) and major clinical
adverse events (b) according to different C-ACS-RS group or
Bio-C-CACS-RS group
Fig. 1 Area under the receiver operating characteristic curve of the C-ACS and Bio-C-CACS-RS group for predicting in-hospital mortality (a) and
major clinical adverse events (b)
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coronary angiography, but this scoring method cannot
be used in clinical practice before the PCI.
Although the above risk-scoring systems were demon-
strated the good predictive value for the clinical out-
comes for STEMI patients, they are limited due to their
relative complexity, the requirement of data calculation,
and the required the procedure related variables. In
contrast, the CACS-RS only requires basic demographic
and initial hemodynamic data, which can be acquired in
the emergency department, or possibly prior to arrival at
the hospital.
Despite its simplicity, the CACS-RS had good predictive
value for clinical outcomes. The C statistic of in hospital
mortality was 0.683. The CACS-RS was first developed by
Huynh et al, who performed their research study to
include the ACS patients, most of whom were without
ST-segment elevation; the score was demonstrated to have
good predictive values for short- and long-term mortality
of ACS patients [6]. The C statistic in this previous study
was similar to the findings in the present study (0.73 vs.
0.68), which included only STEMI patients. More recently,
two published studies have validated the clinical useful-
ness of CACS-RS in ACS patients. One study reported
that CACS-RS performed well in predicting hospital mor-
tality in a contemporary ACS population outside North
America [20]. The other study showed that CACS-RS was
the strongest predictor of in-hospital mortality in all ACS
patients in western Romania [21]. However, we propose
that the present study is the first to further validate the
predictive value of the C-ACS score in a selected STEMI
patient population. The difference in C-statistic analysis
among these researches might be related to the differences
in patient populations studied, and on the characters of
the patients included in the studies. However, the CACS-
RS had acceptable predictive value for STEMI patients,
and permits rapid stratification of patients with STEMI,
and would be welcomed for used by busy clinicians, be-
cause it is simple and can be used as an initial risk-
assessment tools by health care professionals without ad-
vanced medical training.
In addition, although more biomarkers are being added
to develop risk clinical scoring systems, many new bio-
markers still have not been taken account into the CACS-
RS. NT-pro-BNP, which is influenced both by cardiac and
renal function, can be quickly measured by the bedside,
and is increasingly shown to be predictive of short- and
long-term outcomes following STEMI [22]. The current
clinical guidelines also recommended that the use of se-
lected newer biomarkers, especially NT-pro-BNP, may
provide additional prognostic information in patients with
non–ST-elevation ACS. Lee et al found that an improve-
ment in the ability of the clinical SYNTAX score to pre-
dict 1-year major adverse cardiovascular events can be
achieved by combining the clinical SYNTAX score with
an NT-pro-BNP [23]. Similar results have been found in
the study performed by Grabowski et al. Admission of
BNP adds significant prognostic information in addition
to that of Killip classes and TIMI risk score in STEMI
patients [24]. However, another study showed that NT-
pro-BNP did not increase the prognostic accuracy of the
GRACE risk score in patients with ACS [25]. To date, it
has been unclear whether NT-pro-BNP could provide
additional predictive value for CACS-RS. The present
study found that adding the NT-pro-BNP to the CACS-
RS could increase the predictive value for patient clinical
outcome. This is unsurprising, because STEMI patients
with significant left ventricular dysfunction appear to be at
low risk based on the CACS-RS if the blood pressure or
heart rate is within the normal range, but the risk increase
with increased NT-pro-BNP levels.
It is important to bear in mind that risk scores only based
on the clinical characteristic are supplementary tools and
are no replacement for clinical judgment or biomarker
measurement, but combining them could have a beneficial
cumulative effect. According to the guideline’s recommen-
dation that risk assessment is a continuous process that
should be repeated throughout the hospitalization duration
and at time of discharge, after we easily used the CACS-RS
to identify patients at risk of poor clinical outcome at the
first medical contact, we should re-calculate the CACS-RS,
and add the NT-pro-BNP to the CACS-RS to evaluate the
risks for patients during in-hospital stay or following
hospital discharge.
Clinical implications
The results of the present study may have important clin-
ical implications. The C-ACS-RS permits rapid stratifica-
tion of STEMI patients. Because it is simple and easy to
memorize and calculate, it can be rapidly applied at the
first medical contact. In particular, the combined applica-
tion of the C-ACSRS with the plasma NT-pro-BNP levels
on admission serves to identify high-risk patients. The
effective risk stratification provided may be of specific
value for early therapeutic decision making and patient
treatment in the different risk of STEMI patients.
Limitations
The current study had several limitations. Firstly, It
was a single-center, observational study, including a
relatively small number of STEMI patients. The re-
sults of a single study should be interpreted with cau-
tion. In addition, we did not measure NT-pro-BNP
concentrations at long-term follow up, such as at 3
months or at 1 year. Thirdly, C-ACS-Rs lacks preci-
sion, being more of a categorical than a continuous
scoring system. The Killip class evaluation is totally
dependent on the clinical evaluation and expertise of
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the examiner. However, this scoring system is simple
and easy to apply.
Conclusions
In conclusion, for the fist time, the present study vali-
dated the predictive value of C-ACS-RS in STEMI pa-
tients. The combination of C-ACS-RS and NT-pro-BNP
could result in a more accurate prediction for clinical
outcomes in these patients.
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